XENON PHARMACEUTICALS INC's ticker is XENE and the CUSIP is 98420N105. A total of 184 filers reported holding XENON PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 2.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $7,400,559 | -11.7% | 216,644 | -0.5% | 1.36% | -6.7% |
| Q2 2023 | $8,382,990 | -15.5% | 217,740 | -21.5% | 1.45% | -32.7% |
| Q1 2023 | $9,923,959 | +6.9% | 277,283 | +17.7% | 2.16% | -12.7% |
| Q4 2022 | $9,285,410 | +15.5% | 235,491 | +5.8% | 2.47% | +8.2% |
| Q3 2022 | $8,036,000 | -10.3% | 222,597 | -24.4% | 2.28% | -30.8% |
| Q2 2022 | $8,960,000 | -3.6% | 294,559 | -3.2% | 3.30% | +21.3% |
| Q1 2022 | $9,299,000 | -17.4% | 304,186 | -15.6% | 2.72% | +9.5% |
| Q4 2021 | $11,262,000 | +136.8% | 360,502 | +15.8% | 2.48% | +106.6% |
| Q3 2021 | $4,755,000 | -36.3% | 311,207 | -22.4% | 1.20% | -26.3% |
| Q2 2021 | $7,470,000 | +11.5% | 401,207 | +7.2% | 1.63% | +5.0% |
| Q1 2021 | $6,702,000 | +20.5% | 374,395 | +3.5% | 1.56% | +9.1% |
| Q4 2020 | $5,563,000 | +8.1% | 361,689 | -22.2% | 1.42% | +4.5% |
| Q3 2020 | $5,146,000 | -30.5% | 464,825 | -21.3% | 1.36% | -34.6% |
| Q2 2020 | $7,402,000 | +10.6% | 590,267 | 0.0% | 2.08% | -32.8% |
| Q1 2020 | $6,694,000 | -13.2% | 590,267 | +0.4% | 3.10% | +39.4% |
| Q4 2019 | $7,709,000 | – | 588,059 | – | 2.22% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Ghost Tree Capital, LLC | 850,000 | $15,215,000 | 3.58% |
| ACUTA CAPITAL PARTNERS, LLC | 412,500 | $7,384,000 | 2.66% |
| BVF INC/IL | 3,481,778 | $62,324,000 | 2.34% |
| Soleus Capital Management, L.P. | 708,117 | $12,675,000 | 2.28% |
| COMMODORE CAPITAL LP | 301,392 | $5,395,000 | 2.15% |
| DAFNA Capital Management LLC | 406,535 | $7,277,000 | 1.73% |
| Parkman Healthcare Partners LLC | 374,395 | $6,702,000 | 1.56% |
| Avoro Capital Advisors LLC | 3,650,000 | $65,335,000 | 1.13% |
| KNOTT DAVID M | 144,101 | $2,579,000 | 1.10% |
| Orbimed Advisors | 2,497,917 | $44,713,000 | 0.42% |